FelixYi-ChungFengMD

Vice Chair for Faculty Development & Translational Research, Dept of Radiation Oncology Associate Professor of Radiation Oncology, Urology, and Medicine Helen Diller Family Comprehensive Cancer Center University of California at San Francisco

Join to view full profile

Dr. Feng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feng's full profile

Already have an account?

Office
1825 4th St
# L1101
San Francisco, CA 94143
Phone+1 415-502-7222

Education & Training

University of MichiganResidency, Radiation Oncology, 2003 - 2010
University of MichiganResidency, Radiology-Diagnostic, 2003 - 2005
Trinity Health Ann Arbor HospitalInternship, Internal Medicine, 2002 - 2003
Washington University in St. Louis School of MedicineClass of 2002

Certifications & Licensure

CA State Medical License 2016 - 2025
MI State Medical License 2002 - 2017
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma Start of enrollment: 2014 May 01
Terminated
Not Applicable
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Start of enrollment: 2017 Jan 12
Active, not recruiting
Phase 2
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER Start of enrollment: 2018 Apr 27
Active, not recruiting
Phase 2
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery Start of enrollment: 2019 Apr 15
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.
Jarey H Wang, Matthew P Deek, Adrianna A Mendes, Yang Song, Amol Shetty
Radiotherapy and Oncology. 2025-01-01
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate.
Xuanrong Chen, Michael A Augello, Deli Liu, Kevin Lin, Alex Hakansson
Nature Communications. 2024-12-13
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Jonathan Chou, Troy M Robinson, Emily A Egusa, Roshan Lodha, Meng Zhang
Clinical Cancer Research. 2024-12-02

Journal Articles

Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the Internationa...
Michael J Zelefsky, Matthew R Cooperberg, Brian J Davis, Eric M Horwitz, Martha K Terris, Christopher L Amling, Christopher J Kane, Curtiland Deville, Theodore L Dewee..., JAMA Oncology
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
Melody Xu, Felix Y Feng, Corey Speers, Shuang G Zhao, S Laura Chang, Journal of the National Cancer Institute

Press Mentions

Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley RossJanuary 22nd, 2023
Who Needs Systemic Treatment with Salvage Radiotherapy? APCCC 2022 Presentation - Brandon MahalAugust 11th, 2022
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan SprattAugust 18th, 2021
Join now to see all